Anti-diabetic activity of stigmasterol from soybean oil by targeting the GLUT4 glucose transporter

Food and Nutrition Research

Volumn 61, Issue , 2017, Pages

  Wang, Jialin ^a   Huang, Mi ^a   Yang, Jie ^a   Ma, Xinhua ^a   Zheng, Sijian ^a   Deng, Shihao ^a   Huang, Yun ^a   Yang, Xinzhou ^a   Zhao, Ping ^a  

^a SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

Anti diabetic agents; Glucose transporter 4 (GLUT4); Insulin resistance; KK Ay mice; L6 cells; Stigmasterol

Indexed keywords

CHOLESTEROL; GLUCOSE TRANSPORTER 4; METFORMIN; SOYBEAN OIL; STIGMASTEROL; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; KK-AY MOUSE; L6 CELL LINE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; WHITE ADIPOSE TISSUE;

EID: 85049007944     PISSN: 16546628     EISSN: None     Source Type: Journal    
DOI: 10.1080/16546628.2017.1364117     Document Type: Article

References (49)

1. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–321.
2. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431.
4. Maruthur NM, Gribble MO, Bennett WL, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37:876–886.
5. Englyst KN, Englyst HN, Hudson GJ, et al. Rapidly available glucose in foods: an in vitro measurement that reflects the glycemic response. Am J Clin Nutr. 1999;69:448–454.
6. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87:507–520.
7. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12:566–592.
8. Tan M-J, Ye J-M, Turner N, et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol. 2008;15:263–273.
9. Wu X, Li Y, Wang Q, et al. Effects of berberine and pomegranate seed oil on plasma phospholipid metabolites associated with risks of type 2 diabetes mellitus by U-HPLC/Q-TOF-MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1007:110–120.
10. Lin C-F, Kuo Y-T, Chen T-Y, et al. Quercetin-rich Guava (Psidium guajava) juice in combination with trehalose reduces autophagy, apoptosis and pyroptosis formation in the kidney and pancreas of type II diabetic rats. Molecules. 2016;21:334.
11. Yin J, Zhang H-J, Ye J-P. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 2008;8:99–111.
12. Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res. 2008;52:1811.
13. Li C, Liu Y, Xie Z, et al. Stigmasterol protects against Ang II-induced proliferation of the A7r5 aortic smooth muscle cell-line. Food Funct. 2015;6:2266–2272.
14. Gabay O, Sanchez C, Salvat C, et al. Stigmasterol: a phytosterol with potentialanti-osteoarthritic properties. Osteoarthritis Cartilage. 2010;18:106–116.
15. Zielińska S, Matkowski A. Phytochemistry and bioactivity of aromatic and medicinal plants from the genus Agastache (Lamiaceae). Phytochem Rev. 2014;13:391–416.
16. Casal JJ, Bollini M, Lombardo ME, et al. Thalidomide analogues: tumor necrosis factor-alpha inhibitors and their evaluation as anti-inflammatory agents. Eur J Pharm Sci. 2016;83:114–119.
17. Kim Y-S, Li X-F, Kang K-H, et al. Stigmasterol isolated from marine microalgae Navicula incerta induces apoptosis in human hepatoma HepG2 cells. BMB Rep. 2014;47:433–438.
18. Ramu R, Shirahatti PS, Nayakavadi S, et al. The effect of a plant extract enriched in stigmasterol and β-sitosterol on glycaemic status and glucose metabolism in alloxan-induced diabetic rats. Food Funct. 2016;7:3999–4011.
19. De-Eknamkul W, Potduang B. Biosynthesis of β-sitosterol and stigmasterol in Croton sublyratus proceeds via a mixed origin of isoprene units. Phytochemistry. 2003;62:389–398.
20. Kim G-C, Kim J-S, Kim G-M, et al. Anti-adipogenic effects of Tropaeolum majus (nasturtium) ethanol extract on 3T3-L1 cells. Food Nutr Res. 2017;61:1339555.
21. Huang M, Deng S-H, Han Q-Q, et al. Hypoglycemic activity and the potential mechanism of the flavonoid rich extract from Sophora tonkinensis Gagnep. in KK-Ay mice. Front Pharmacol. 2016;5(7):288.
22. Huang M, Zhao P, Xiong MR, et al. Antidiabetic activity of perylenequinonoid-rich extract from Shiraia bambu-sicola in KK-Ay mice with spontaneous type 2 diabetes mellitus. J Ethnopharmacol. 2016;191:71–81.
23. Kumar A, Lawrence JC Jr, Jung D-Y, et al. Fat cell-specific ablation of rictor in mice impairs insulin-regu-lated fat cell and whole-body glucose and lipid metabolism. Diabetes. 2010;59:1397–1406.
24. Rubin BR, Bogan JS. Intracellular retention and insulin-stimulated mobilization of GLUT4 glucose transporters. Vitam Horm. 2009;80:155–192.
25. Kondo K, Nozawa K, Tomita T, et al. Inbred strains originated came from Japanese native mice. Bull Exp Anim. 1957;6:107.
26. Nishimura M. Breeding of mice strains for diabetes mellitus. Exp Anim. 1969;18:147–157.
27. Kato T, Shimano H, Yamamoto T, et al. Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes. 2008;57:2382–2392.
28. Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668–2675.
29. Stephenne X, Foretz M, Taleux N, et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia. 2011;54:3101–3110.
30. Arshadi S, Azarbayjani MA, Hajiaghaalipour F, et al. Evaluation of Trigonella foenum-graecum extract in combination with swimming exercise compared to glib-enclamide consumption on type 2 diabetic rodents. Food Nutr Res. 2015;59:29717.
31. Camer D, Yu Y, Szabo A, et al. The molecular mechanisms underpinning the therapeutic properties of oleano-lic acid, its isomer and derivatives for type 2 diabetes and associated complications. Mol Nutr Food Res. 2014;58:1750–1759.
32. Morio B, Fardet A, Legrand P, et al. Involvement of dietary saturated fats, from all sources or of dairy origin only, in insulin resistance and type 2 diabetes. Nutr Rev. 2016;74:33–47.
33. Schofield CJ, Sutherland C. Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes. Diabet Med. 2012;29:972–979.
34. Sanshiro T, Francis K, Yoshikazu T. Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4:93.
35. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821– 1830.
36. Bjørndal B, Burri L, Staalesen V, et al. Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J Obes. 2011;2011:1–15.
37. Leung PS. The potential protective action of vitamin D in hepatic insulin resistance and pancreatic islet dysfunction in type 2 diabetes mellitus. Nutrients. 2016;8:147.
38. Jiao J, Dou L, Li M, et al. NADPH oxidase 2 plays a critical role in dysfunction and apoptosis of pancreatic β-cells induced by very low-density lipoprotein. Mol Cell Biochem. 2012;370:103–113.
39. Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol. 2012;13:383–396.
40. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. 2002;3:267–277.
41. Liu F, Dallas YQ, Castriota G, et al. Development of a novel GLUT4 translocation assay for identifying potential novel therapeutic targets for insulin sensitization. Biochem J. 2009;418:413–420.
42. Ivy JL, Kuo C-H. Regulation of GLUT4 protein and glycogen synthase during muscle glycogen synthesis after exercise. Acta Physiol Scand. 1998;162:295–304.
43. Berger J, Biswas C, Vicario PP, et al. Decreased expression of the insulin-responsive glucose transporter in diabetes and fasting. Nature. 1989;340:70–72.
44. Sivitz WI, DeSautel SL, Kayano T, et al. Regulation of glucose transporter messenger RNA in insulin-deficient states. Nature. 1989;340:72–74.
45. Treadway JL, Hargrove DM, Nardone NA, et al. Enhanced peripheral glucose utilization in transgenic mice expressing the human GLUT4 gene. J Biol Chem. 1994;269:29956–29961.
46. Yang X-Z, Yang J, Xu C, et al. Antidiabetic effects of flavonoids from Sophora flavescens EtOAc extract in type 2 diabetic KK-ay mice. J Ethnopharmacol. 2015;171:161–170.
47. Wang C, Yang J, Zhao P, et al. Chemical constituents from Eucalyptus citriodora Hook leaves and their glucose transporter 4 translocation activities. Bioorg Med Chem Lett. 2014;24:3096–3099.
48. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409:729–733.
49. Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med. 2000;6:924–928.